

Index

- Analysis of Means (ANOM)
 - compared with ANOVA, 194
 - experimental design data, 193–194
 - proportions, 128–129
 - variances, 84
- Bioequivalence testing, 215, 251–252
- Competing probability approach, 32, 254
- Cohen's effect sizes, 191–192
- Confidence intervals, 2–3
 - on sample size and power, 67–68
 - relationship to hypothesis tests, 5–6
 - sample sizes for, 33–36, 105
 - for a proportion
 - exact (Clopper–Pearson) interval, 105
 - normal approximation approach, 110–112
 - with a finite population, 112
- Control charts, 277
 - adaptive, 293
 - attribute charts, 286–289
 - Ryan–Schwertman limits, 286–287
 - average run length (ARL), 280–283, 288, 290
 - CUSUM and EWMA charts, 289–290
 - EWMA for autocorrelated data, 293
 - variations, 291
 - medical applications, 296–297
 - multivariate, 295–296
 - Phase 1 and Phase 2, 277
 - regression and cause-selecting charts, 293–294
 - S -chart and S^2 -chart, 284–285
 - Shewhart measurement charts, 278
 - Stage 1 and Stage 2, 277
 - \bar{X} -chart, 282–283
- Cost of sampling, 40
- Ethical considerations, 40–42
- Equivalence testing, 10–11, 43–45, 229
 - example, 44–45
 - for one proportion, 109–110
- Evidential approach, 32
- External pilot study, 20
- Finite populations, 32–33
- Fisher's exact test, 121–122
- Generalized linear models
 - sample size determination, 165
- Hypothesis testing, 1–8
 - criticisms, 2
 - limitations, 5
 - one-sided tests versus two-sided tests, 5, 41–42
 - p -value, 3–5
 - misinterpretations, 4

- Hypothesis testing (*Continued*)
 - power of a test, 7
 - significance level, 5
 - Type I error, 8, 21, 75
 - Type II error, 3–5, 8, 69, 75
 - probability of, 8
- Internal pilot study, 20–22
 - compared with external pilot study, 20–21
 - for parameter estimation, 20–21
- Journal of the American Medical Association*, 253, 263
- Lancet*, 253
- Measurement system appraisal, 300
- Meta-analyses of clinical trials, 256
- Microarray experiments, 219–220
- New England Journal of Medicine*, 253
- Noninferiority tests, 11, 229
 - for one proportion, 109
 - for two proportions, 125
- Pharmacodynamic experiments, 253
- Pharmacokinetic experiments, 229, 253
- Pharmacogenetic experiments, 253
- Pilot studies, 26
- Power
 - assumed versus actual power, 59–60, 196
 - computed using noncentrality parameter, 188, 199–200, 221, 347
 - definition of, 188
 - conditional, 10
 - difficulty assessing power with
 - nonparametric methods, 323–324, 326
 - in clinical studies, 252–253
 - observed, 9
 - obtained using Lynch's tables for
 - experimental designs, 207–208, 210
 - of control charts, 280
 - predictive, 10
 - realistic values of power used in sample
 - size determination, 39
 - retrospective, 9
 - criticism, 9–10
 - target, 59–60
 - using the software Design-Expert with
 - experimental designs, 207–208
- Preclinical experimentation, 253
- Probability assessment approach, 31–32
- Probability of underestimating sample size, 23
- QT/QTc studies, 258
- Reproducibility probability approach, 32
- Sample size determination
 - acceptance sampling, 300–301
 - agreement studies, 351
 - agricultural applications, 350–351
 - AMOVA (analysis of molecular variance), 352
 - Bayesian approaches, 18–19, 24, 30–31
 - case-control studies, 341
 - clinical trials
 - adaptive, 248
 - Bayesian methods, 255
 - cluster randomized trials, 247
 - combination treatments, 251
 - ethical considerations, 252
 - general considerations, 243–246
 - multiple tests, 250
 - noninferiority, 249
 - Phase I, 246–247, 260
 - Phase II, 246–248, 260, 262
 - cancer trials, 247
 - Phase III, 246–248
 - Phase IV, 248
 - repeated measurements, 249–250
 - software output, 261–263
 - using conditional power and predictive
 - power, 257
 - using costs, 256
 - using historical controls, 250
 - using internal pilot studies, 250
 - using simulation, 246–247
 - vaccine efficacy studies, 251
- cluster sampling, 345
- confidence intervals, 33–34

- control charts
 - CUSUM and EWMA charts
 - subgroup size considerations, 290–292
 - determining subgroup size
 - using software simulations, 281–283
 - for Stage 1, 279–280, 302
 - for Stage 2, 280, 302
 - variable subgroup size in Stage 2, 279
- correlation, 172–176
 - confidence intervals, 174–175
 - intraclass correlation, 175
 - two correlations, 175–176
- epidemiology, 342
- estimating population totals, 38
- estimating sigma without data, 27
- estimating the number of unseen species, 351
- experimental designs
 - 2^k designs, 205–209
 - 2^2 design, 206
 - unreplicated, 206–207
 - 2^{k-p} designs, 209–210
 - Analysis of Covariance (ANCOVA), 196–197
 - Bayesian, 229
 - block designs
 - incomplete block designs
 - balanced, 198
 - partially balanced, 199
 - randomized complete block designs, 197–198
 - completely randomized designs, 197
 - crossover designs, 202, 215–218, 230
 - detecting conditional effects, 210–211
 - for computer experiments, 228–229
 - for nonnormal responses, 225–226
 - Poisson distribution, 226
 - Latin square designs, 199–203
 - Graeco-Latin square designs, 202–203
 - using multiple Latin squares, 200–201
 - multiple comparisons, 192–193
 - nested designs, 224–225
 - nested factor, 224
 - nested factorial, 224
 - one factor, two fixed levels, 184–187
 - power, 185–186
 - unequal sample sizes, 186–187
 - one factor, more than two fixed levels, 187–192
 - hand calculation formulas, 28–29
 - unequal sample sizes, 195–196
 - Plackett–Burman designs, 220–222
 - ray designs, 225
 - repeated measures designs, 212–214
 - split-plot designs, 222–224
 - strip-plot designs, 222–224
 - two factors, 203–205
 - use of Excel spreadsheet, 226
 - useful tables, 233
 - with random factors, 227–228
 - zero patient designs, 228
- factor analysis, 346
- for miscellaneous types of studies, 352–353
- genome-wide association studies, 351
- in auditing, 37
- inaccuracy of calculations, 17
- longitudinal studies, 342
- maximum error of estimation, 34–37, 86–91, 111–112
 - relative precision, 93–94
 - using prediction bound for sigma, 86
- microarray studies, 343
- means
 - Bayesian methods, 81
 - one mean, 58–63
 - confidence interval, 63–65, 84–88
 - adaptive, 85
 - exponential distribution, 71
 - unequal sample sizes, 74
 - using upper confidence bound on sigma, 64, 67–68
 - approach investigated, 68
 - two means, 71–81
 - dependent samples, 78–81, 90–91
 - confidence interval on difference between means, 90–91
 - using coefficient of variation, 65–66
 - using the t distribution, 70
 - robustness, 70
- measures of agreement, 350
- meta-analyses, 343
- multilevel modeling, 349

Sample size determination (*Continued*)

- multinomial probabilities, 129–130
- multivariate methods, 346–348
 - Hotelling's T^2 procedure, 346–348
 - MANOVA (multivariate analysis of variance), 346
- national security, 352
- nonparametric tests
 - contingency tables, 334
 - Kruskal–Wallis one-way ANOVA, 331
 - obstacles in sample size determination, 329
 - Mann–Whitney test, 327–330
 - McNemar's test, 334
 - quasi-likelihood, 334–335
 - rank correlation coefficients, 335
 - sample size determined using
 - asymptotic relative efficiency, 325, 329
 - sign test, 331–334
 - van Elteren test, 331
 - Wilcoxon one-sample test, 324–325
 - for paired data, 327
- not provided in most studies with results
 - not having statistical significance, 57
- poor ad hoc approaches, 19
- prediction intervals, 349–350
- process capability indices, 297–298
- proportions
 - multiple proportions, 126–127
 - chi-square test, 127
 - one proportion, 103
 - Bayesian approaches, 115
 - differing software solutions, 108–109
 - exact approach, 113–114
 - with arcsine transformation, 104
 - with continuity correction, 107–108
 - two proportions, 115–126
 - approximation, 118
 - arcsine transformation, 116
 - Bayesian method, 126
 - correlated proportions (McNemar's test), 123–124
 - equivalence tests, 124–125
 - linear trend (Cochran–Armitage test), 125–126
 - unequal sample sizes, 120
 - with continuity correction, 119–120

rates

- assuming Poisson distribution, 130, 133
- one rate, 130–132
 - pilot study, 132
- two rates, 132–135
 - using variance stabilizing transformation, 134
- receiver operating characteristic ROC curves, 343
- regression models
 - Cox regression, 167–169, 171
 - possible problems using maximum likelihood, 168
 - Draper–Smith rule of thumb, 148
 - effect sizes, 150
 - logistic regression, 155
 - assuming use of Wald test, 158, 162
 - complexities, 156–157
 - disagreements among software solutions, 160
 - exact logistic regression, 167
 - software, 167
 - multiple logistic regression, 163–165
 - measurement error, 165
 - applet, 165
 - possible problems interpreting coefficients, 163
 - simple rule of thumb for determining sample size, 164
 - using variance inflation factor, 163
 - concern over such use, 163–164
 - ordinal logistic regression, 166–167
 - polytomous logistic regression, 165
 - simple logistic regression, 156–162
 - binary covariate, 162
 - using Demidenko's applet, 158
 - using two-sample t -test approach, 157
 - new approach using Wetz criterion
 - in simple linear regression, 147–148
 - in multiple linear regression, 151–154
 - nonlinear regression, 172
 - obstacles in simple linear regression, 146

- problems interpreting coefficients of
 - random regressors, 150
- obstacles in multiple linear regression, 150
- Poisson regression, 169–172
 - exact Poisson regression, 169–170
 - using Soper's applet, 148–149, 152
- reliability and life testing, 301, 317–318
- sample surveys, 344
 - vegetation surveys, 344
- sequential sample sizes, 343–344
- Slovin's formula, 20
- spatial statistics, 350
- standard deviation, 81
- structural equation modeling, 348–349
- survey results, 259
- survival studies, 307
 - Cox proportional hazards model, 314–315
 - adjusting for covariates, 315
 - effect on sample size, 315
 - Freedman method, 311–312
 - joint modeling of longitudinal and survival data, 315–316
 - logrank test, 308–311
 - multistage designs, 316
 - number of deaths needed, 310
 - sample size challenges, 308
 - suggested formulas, 310–311
 - Tarone–Ware test, 313
 - Wilcoxon–Breslow–Gehan test
 - lack of sample size software, 313
- test reliability, 351
- tolerance intervals, 298–300
- using coefficient of variation, 113
- using finite population correction factor (fpc), 36–39, 195
- using simplified, approximate formulas, 72–74
- using standard deviation units, 26
- variances, 81–84
 - more than two, 84
 - one variance, 81–83
 - approximation, 82–83
 - confidence interval, 91–92
 - one-sided confidence bound, 92–93
 - two variances, 83
 - dependent samples, 84
 - using Levene's test, 84
- Software
 - East, 260
 - ExpDesign Studio, 260
 - G*Power, 47, 84, 117, 131, 136, 170, 174–175, 230–231, 326–327, 329, 336, 346
 - Java applets, 45–47, 135, 158, 174, 186, 260, 317
 - Lenth's applet, 22–23, 46, 58, 65, 74, 77, 80, 109, 117, 121, 131–132, 135, 138, 147, 149, 174, 186–187, 190, 195, 197–198, 200–202, 212, 220, 222–224, 227–228, 230
 - Mathematica, 189, 336
 - MATLAB, 189
 - MINITAB, 7, 46, 60, 62, 65, 76, 79–80, 84–85, 89, 93–94, 105–106, 109, 113, 117, 121–122, 128, 131–133, 135, 175, 185–186, 188, 195, 198, 204–205, 208–209, 212, 217, 220–221, 228, 230–231, 288, 301, 327
 - macro for computing power for fixed effects balanced designs, 230
 - MLPowSim, 349
 - N Solution, 260
 - nQuery Advisor, 7, 27, 46, 65, 74–77, 84–85, 87–90, 93–94, 106, 109, 117, 121, 125–127, 131, 136, 138, 154, 160, 162, 164, 174, 187, 195, 205, 217, 231–232, 312, 316, 329, 331, 336, 350
 - PASS, 7, 27, 29–30, 33, 35, 46–47, 60, 62, 65, 72, 74–77, 79, 82–85, 87–94, 103, 106, 109–110, 113, 117, 121–127, 130–131, 133–135, 147–149, 154–155, 158–162, 164, 168–171, 174–176, 187, 194–198, 202–204, 213–214, 216–218, 220, 231–232, 260, 262, 282–285, 287–288, 290–293, 301, 311–312, 316, 318, 324, 326–329, 331–334, 336, 346–347, 350

Software (*Continued*)

Power and Precision, 7, 46, 60, 62, 71,
75–76, 80, 84, 93–94, 104,
106–107, 109, 116–117,
121–122, 125, 131, 135–136,
153–154, 158, 161, 162, 164,
174–176, 187, 189–190,
195, 197, 201–203, 230,
316

R code/packages, 24, 69, 135, 189, 220,
328, 342–343

SAS Software/programs, 45, 75, 81, 94,
161, 198, 230, 232, 263, 331,
346

SiZ, 46, 109, 121, 131, 158, 160–162,
164, 217, 350

Soper's applets, 148–149, 152–154, 173,
348

S-Plus, 24

Stata, 7, 46, 94–95, 121, 131, 135–136,
158, 168, 170, 173, 262,
316–317, 342

STATGRAPHICS, 301

Standardized effect sizes, 42–43
criticism, 42–43

Superiority testing, 11

Value of information methods, 17, 256